Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) EBIT Margin (2019 - 2025)

C4 Therapeutics' EBIT Margin history spans 7 years, with the latest figure at 210.1% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 51829.0% year-over-year to 210.1%; the TTM value through Dec 2025 reached 320.53%, up 1561.0%, while the annual FY2025 figure was 320.53%, 1561.0% up from the prior year.
  • EBIT Margin reached 210.1% in Q4 2025 per CCCC's latest filing, up from 306.43% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 75.98% in Q4 2021 to a low of 1410.21% in Q2 2023.
  • Average EBIT Margin over 5 years is 528.92%, with a median of 354.68% recorded in 2025.
  • Peak YoY movement for EBIT Margin: tumbled -126575bps in 2022, then skyrocketed 123162bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 75.98% in 2021, then plummeted by -1666bps to 1341.73% in 2022, then increased by 14bps to 1147.72% in 2023, then surged by 37bps to 728.39% in 2024, then soared by 71bps to 210.1% in 2025.
  • Per Business Quant, the three most recent readings for CCCC's EBIT Margin are 210.1% (Q4 2025), 306.43% (Q3 2025), and 440.99% (Q2 2025).